Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy
- Citation:
- Clin Cancer Res vol 23 (22) 6802-6811
- Year:
- 2017
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 6
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10CA032291, U10CA077651, U10CA007968, U10CA180791, U10CA180867, 5UO1CA157703, 3U10CA180821-03S3, PC121341, U01 CA157703, U10 CA077202, U10 CA031946, U10 CA180821, U10 CA180863
- Corr. Author:
- Authors:
- Himisha Beltran Alexander W Wyatt Edmund C Chedgy Adam Donoghue Matti Annala Evan W Warner Kevin Beja Michael Sigouros Fan Mo Ladan Fazli Colin C Collins James Eastham Michael Morris Mary-Ellen Taplin Andrea Sboner Susan Halabi Martin E Gleave
- Networks:
- LAPS-MA036, LAPS-MD017, LAPS-NY016
- Study
- CALGB-90203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- high-risk prostate cancer, neoadjuvant, docetaxel, ADT, genomics, integrative molecular analysis